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ABSTRACT 
International Journal of Exercise Science 8(4): 394-402, 2015. Endurance performance 
and peak oxygen uptake (VO2peak) decline as altitude increases. Some data exist suggesting that 
quercetin supplementation improves aerobic capacity in trained and untrained individuals at 
sea-level (normobaric normoxic conditions). Few studies have examined the effects of quercetin 
on endurance performance during simulated altitude exposure (normobaric hypoxic conditions). 
The purpose of this study was to determine the effects of consuming 1000 mg·day-1 of quercetin 
for two weeks on cycling VO2peak in healthy trained male cyclists performing under normobaric 
normoxic and hypoxic conditions (NP and HP, respectively). Fourteen age-matched healthy male 
subjects were randomized to either a placebo or quercetin group. Baseline and post 
supplementation VO2peak values were quantified during incremental cycling under normobaric 
normoxic (FIO2 = 20.9%) and normobaric hypoxic (FIO2 = 13.6 + 0.2%) conditions. Subjects 
consumed capsules twice daily with either 500 mg quercetin or placebo (Tang) for two weeks and 
were re-assessed. Test order was randomized and assessments were separated by 48-72 hours. At 
baseline, there were no significant differences between groups for VO2peak normobaric normoxic 
trials (NPbaseline Placebo vs. NPbaseline Quercetin = 58.7+8.8 and 61.5+7.9 ml . kg-1 . min-1, 
respectively, p = 0.541) and normobaric  hypoxic trials (HPbaseline Placebo vs. HPbaseline Quercetin = 
48.5+8.3 and 50.8+4.8 ml . kg-1 . min-1, respectively, p = 0.534). No significant differences were 
found after treatment (Placebo: NPbaseline vs. NPpost = 58.7+ 8.8 and 56.7+7.4 ml . kg-1 . min-1, 
respectively, p = 0.10; HPbaseline vs .HPpost = 48.5+8.3 and 47.1+8.3, respectively, p = 0.50; 
Quercetin: NPbaseline vs. NPpost = 61.5+7.9 and 62.4+7.3 ml . kg-1 . min-1, respectively, p = 0.558; 
HPbaseline vs. HPpost = 50.8+4.8 and 51.2+3.8 ml . kg-1 . min-1, respectively, p= 0.656. These data 
suggest that short-term quercetin supplementation at 1000 mg . day-1 does not affect VO2peak 
elicited via incremental maximal cycle testing under normobaric normoxic and hypoxic 
conditions in trained male cyclists. Furthermore, quercetin supplementation did not attenuate the 
decline in VO2peak that was evident in the normobaric hypoxic condition. 
 




In recent years, much attention has been 
given to the role of dietary antioxidants in 
preventing disease and improving overall 
health.  Quercetin, a polyphenolic 
flavonoid, is a naturally occurring 
substance that is found in a variety of food.  
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Common food sources of quercetin include 
tea, onions, apples, peppers, blueberries 
and dark green vegetables, with the 
average intake of U.S. adults at 
approximately 4 mg . day-1.  However, daily 
intakes may be as high as 200 – 500 mg in 
individuals consuming a diet high in fruits 
and vegetables (5).  Although not entirely 
conclusive, epidemiologic studies provide 
evidence that self-selected diets high in 
quercetin may play a role in preventing 
various diseases.  High quercetin intake has 
been linked to a reduced risk of colorectal, 
kidney, pancreatic, prostate, and lung 
cancer, as well as cardiovascular disease 
(10, 11, 29).  In vitro, animal, and human 
studies have shown that quercetin 
possesses antioxidant, anti-carcinogenic, 
anti-inflammatory, and cardioprotective 
properties (3, 12, 14, 23, 26).  In addition, 
there is evidence that quercetin may lower 
blood pressure through vasodilatory effects 
(14, 19).  Based on these studies, quercetin 
appears to have significant health benefits.   
 
Because of the purported health benefits of 
quercetin, investigators have begun to 
examine the efficacy of quercetin in 
improving athletic performance.  Regular 
aerobic exercise can increase muscle 
mitochondrial density by 20% to 100%, 
depending on the workload (13).  This 
increase in mitochondrial density 
contributes to improved fitness and 
performance by increasing the aerobic 
capacity of skeletal muscle.  Limited data 
show that quercetin may have the ability to 
induce mitochondrial biogenesis and 
improve aerobic exercise performance.  
Human studies have shown that daily 
supplementation of quercetin (500 mg twice 
daily) improves aerobic capacity, time to 
exhaustion, time trial performance, and 
exercise tolerance (20, 21).  Furthermore, 
recent evidence from both animal and 
human studies suggests that quercetin 
supplementation resulted in increased 
mitochondrial capacity, oxidative enzyme 
activity, and increased time to exhaustion 
(8, 9).  Additional data show that quercetin 
may cause vasodilation, resulting in 
improved blood flow (5, 18, 22).  An 
increase in blood flow to working muscle, 
coupled with an increase in mitochondrial 
density, could result in improved 
endurance performance by increasing an 
individual’s aerobic capacity and fat 
utilization.  Although these data support 
the use of quercetin to improve aerobic 
performance, other studies have shown that 
quercetin has no effect on aerobic capacity 
(1, 6).  More work is needed in this area to 
better define the efficacy of quercetin in 
improving athletic performance under 
various conditions.   
 
It is well established that altitude decreases 
VO2peak in humans and evidence suggests 
that oxidative stress increases at altitude 
(16, 27). Consequently, the use of 
nutritional interventions, such as 
antioxidant supplementation to enhance 
antioxidant capacity and prevent and/or 
treat symptoms of acute mountain sickness 
has gained attention.  Although justification 
for their use is not based on scientific 
evidence, Ginkgo Biloba and Hippophae 
rhamnoides L. have been used for centuries 
in Chinese and Tibetan medicine to combat 
AMS (24).  Data from Purushothama et al. 
(2008) show that H. rhamnoides exerted a 
protective effect in rats exposed to hypoxia 
(24).  Quercetin is a major component of 
this supplement (30).  However, there is 
very limited data regarding the efficacy of 
isolated quercetin in attenuating the effects 
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of hypoxia in vivo.  Zhou et al. investigated 
the protective effect of quercetin in rats 
exposed to a chronic (23 h per day) 
hypobaric, hypoxic environment (31).  
Quercetin attenuated the decline in blood 
pH, PO2, SpO2, and PCO2 that occurred in 
the control group.  In addition, quercetin 
increased nitric oxide levels, a potent 
vasodilator (31).  Based on this limited data, 
it is plausible that quercetin may exert 
protective effects in an individual exposed 
to a hypoxic environment.  
 
Significant reductions in VO2peak generally 
occur at an altitude of 1,500 to 1,600 m 
(5,000 ft).  Beyond this altitude, VO2peak 
decreases approximately 8% to 11% for 
every 1,000 m increase (or 3% for every 
1,000 ft increase) (27).  In addition, variables 
such as heart rate, ventilation, and 
perception of fatigue, at rest and during 
exercise, are increased at higher elevation.  
The lack of oxygen at altitude also affects 
substrate metabolism.  At altitude, there is 
an increased reliance carbohydrate for fuel 
since this substrate can be metabolized 
anaerobically (4, 17).  Therefore, aerobic 
exercise at altitude may be limited, in part, 
by glycogen depletion, as this is a very 
limited fuel supply.  Due to the detrimental 
effect of altitude on athletic performance, 
many studies have investigated various 
nutritional strategies in an effort to offset 
the performance decrement typically seen 
in an individual performing in that 
environment.  Recent studies have 
examined the efficacy of antioxidants and 
other nutritional supplements in 1) 
attenuating the decline in VO2max and 2) 
enhancing fat utilization, thus sparing 
glycogen, in individuals exercising at 
altitude.  However, there is very limited 
data regarding the efficacy of quercetin in 
enhancing aerobic performance and fat 
utilization at altitude. The overall goal of 
this investigation is to examine the effect of 
quercetin on peak oxygen uptake (VO2peak) 
in trained individuals exercising under 
normobaric normoxic and hypoxic 





Fourteen healthy male subjects (age: 38.9 + 
9.8 y, weight: 75.7 + 7.9 kg) were recruited 
through flyers posted on the Castleton State 
College campus and throughout the 
Rutland community, and through 
solicitation of the Killington Pico Cycling 
Club.  Prior to data collection, participants 
were advised of the possible risks, methods, 
and potential benefits of participation in the 
study.  A health history questionnaire and 
informed consent (approved by the 
Castleton State College Institutional Review 
Board for research involving human 
subjects) was completed by each subject.   
 
Protocol 
Subjects were age-matched and 
randomized to either a placebo group 
(consumed one capsule twice daily with 
500 mg Tang from the Kraft Foods 
Company, Northfield, IL) or quercetin 
supplementation group (consumed one 
capsule with 500 mg twice daily with 
quercetin from Jarrow Formulas, Los 
Angeles, CA) in a double-blind design. 
Subjects had no significant recent exposure 
to altitude training or racing and were 
asked to maintain their typical training and 
dietary routines for the duration of the 
study. Subjects were instructed to refrain 
from strenuous exercise and excessive 
alcohol for 24 hours prior to testing. 
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Subjects maintained a dietary record for 48 
hours prior to initial testing and were asked 
to match it as closely as possible for each 
successive trial. All maximal trials were 
separated by 48-72 hours. 
 
Metabolic data was collected using a 
ParvoMedics metabolic system 
(ParvoMedics, Salt Lake City, UT). All 
testing was conducted using an 
electronically-braked cycle ergometer 
designed to interface with the subject’s 
personal cycle of choice (Velotron DynaFit 
Pro, Seattle, WA).  Subjects completed a five 
minute warm-up at a workload of 50 watts 
at the start of each trial. Using a continuous 
incremental protocol, workload increased 
by 25 watts per minute until volitional 
exhaustion was achieved. All tests were 
terminated after subjects failed to maintain 
their final workload for 15 seconds and/or 
voluntarily identified that their maximal 
effort was achieved. VO2peak was identified 
as the highest value recorded during the 
final workload achieved by each subject.  
Subjects performed cycling trials under 
normobaric normoxic conditions (FIO2 = 
20.9%, 752 + 4 mmHg) and hypoxic 
conditions (FIO2 = 13.6 + 0.2%, 754 + 3 
mmHg; simulated approximately 3600 
meters above sea-level).  Baseline and post 
treatment normoxic and hypoxic trials were 
randomized and subjects were not 
informed of the trial condition. Hypoxic 
conditions were produced using a hypoxic 
generator (Colorado Altitude Training, 
Louisville, CO) connected to two, 200 L 
Douglas bags that were used to create a 
reservoir of inspiratory gas for the subjects 
during hypoxic trials (Figure 1).  In order to 
avoid subject bias, this method was also 
used during the normoxic trials with the 
Douglas bags filled with 20.9% O2. 
 
Figure 1. Experimental set up. 
 
Statistical Analysis 
A MANOVA examined oxygen level 
(normoxia/hypoxia), quercetin 
supplementation, and time as independent 
variables and VO2peak and power (w) as 
dependent variables (Wilks’ λ = .095, F(9,4) 
= 4.24, p = .09). Univariate ANOVAs 
examined differences in individual 
dependent variables. Thereafter, post-hoc t-
tests were used to examine pair-wise 
differences. Using Bonferroni correction, a 
family-wise alpha of .05 was maintained for 




VO2peak was not different between groups at 
baseline for normobaric normoxic trials 
(placebo vs. quercetin group = 58.7+8.8 and 
61.5+7.9 ml . kg-1. min-1, respectively, t(12) = 
-.63, p = 0.54) (Table 1) and hypoxic trials 
(placebo vs. quercetin group = 48.5+8.3 and 
50.8 + 4.8 ml . kg-1. min-1, respectively, t(12) 
= -.64, p = 0.53) (Table 2).  There was no 
statistically significant difference found in 
VO2peak during normoxic trials for the 
placebo group when comparing baseline 
values to post placebo supplementation 
values (58.7 + 8.8 and 56.7 + 7.4 ml . kg-1. 
min-1, respectively, t(6) = 1.95, p = 0.10 
(Table 1).  There was no statistically 
QUERCETIN SUPPLEMENTATION AND SIMULATED ALTITUDE PERFORMANCE 
International Journal of Exercise Science                                                          http://www.intjexersci.com 
398 
significant difference found in VO2peak 
during hypoxic trials for the placebo group 
when comparing baseline values to post 
placebo supplementation values (48.5 + 8.3 
and 47.1 + 8.3 ml . kg-1. min-11, respectively, 
t(6) = .72, p = 0.50 (Table 2).  There was no 
statistically significant difference found in 
VO2peak during normoxic trials for the 
quercetin supplementation group when 
comparing baseline values to post 
supplementation values (61.5 + 7.9 and 62.4 
+ 7.3 ml . kg-1. min-1, respectively, t(6) = -.62, 
p = 0.56) (Table 1). There was no statistically 
significant difference found in VO2peak 
during hypoxic trials for the quercetin 
supplementation group when comparing 
baseline values to post supplementation 
values (50.8 + 4.8 and 51.2 + 3.8 ml . kg-1. 
min-1, respectively, t(6) = -.47, p = 0.66) 
(Table 2).  As expected, VO2peak for all 
hypoxic trials was significantly (p < 0.05) 
reduced when compared with normoxic 
trials (baseline normoxia vs. baseline 
hypoxia and post normoxia vs. post 
hypoxia) trails for all groups (range = -
16.9% to -17.9% of baseline VO2peak) (Table 
3). These data suggest that short-term 
quercetin supplementation for 2 weeks at 
1000 mg . day-1 does not improve VO2peak in 
healthy trained male cyclists performing 
under normobaric normooxic and hypoxic 
laboratory conditions. 
 
Table 1. Mean (+ SD) results for VO2peak during 
normoxic trials for placebo and quercetin 
supplementation groups. 
 
Normoxic Trials Peak VO2  
(ml . kg-1 . min-1) 
Placebo baseline 58.7 + 8.8* 
Placebo post 56.7 + 7.4* 
Quercetin baseline 61.5 + 7.9* 
Quercetin post 62.4 + 7.3* 
 
Table 2. Mean (+ SD) results for VO2peak during 
hypoxic trials for placebo and quercetin 
supplementation groups. 
 
Hypoxic Trials Peak VO2  
(ml . kg-1 . min-1) 
Placebo baseline 48.5 + 8.3** 
Placebo post 47.1 + 8.3** 
Quercetin baseline 50.8 + 4.8 ** 
Quercetin post 51.2 + 3.8 ** 
 
Table 3. Mean (+ SD) results for VO2peak comparing 
normoxic and hypoxic trials for placebo and 
quercetin supplementation groups. 
 
Normoxic vs. Hypoxic Trials   Peak VO2  
(ml . kg-1 . min-1) 
 Normoxic Hypoxic % 
Decline 
Placebo baseline  58.7 + 8.8 48.5 + 8.3 17.4† 
Placebo post 56.7 + 7.4 47.1 + 8.3 16.9† 
Quercetin baseline 61.5 + 7.9 50.8 + 4.8  17.4† 
Quercetin post 62.4 + 7.3 51.2 + 3.8  17.9† 




The primary purpose of this investigation 
was to evaluate the effects of quercetin 
supplementation on VO2peak during 
incremental cycle ergometry under 
normobaric hypoxic conditions that 
simulated approximately 3600 meters of 
elevation above sea-level. In addition, the 
effect of quercetin supplementation on 
VO2peak during normobaric normoxic/sea-
level conditions was investigated. We 
report no beneficial effects of 1000 mg . day-
1 of quercetin supplementation for two 
weeks on VO2peak under both hypoxic and 
normoxic conditions. While VO2peak 
responses to normobaric hypoxia after 
quercetin supplementation have not been 
studied, our findings are consistent with 
others who have reported no beneficial 
effects to endurance performance and 
aerobic capacity after short-term (i.e., 2 - 4 
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weeks) quercetin supplementation (3, 4). 
Our findings are contrary to those who 
reported that quercetin supplementation 
improved cycling efficiency, aerobic 
capacity, fat utilization, and time trial 
performance in both trained and untrained 
individuals (7, 8, 9, 21).   
 
Due to controversial findings related to the 
effects of quercetin supplementation on 
factors related to endurance performance in 
humans and animals, researchers have 
addressed the methodological variability of 
several of these studies.  Jin and colleagues 
(2010) have questioned the bioavailability 
of extracted/processed verses natural 
forms of quercetin, suggesting that natural 
forms may be superior to processed forms. 
We chose a processed form for this 
investigation as dosage was easily 
controlled. Dosage has also varied from 
study to study. The 1000 mg . day-1 used 
here is among the higher doses studied, 
although even higher doses may be needed 
to yield beneficial effects (15). It is possible 
that longer duration supplementation (i.e., 
> 4 weeks) and/or higher doses may be 
necessary to induce structural and 
functional biological changes that could 
enhance endurance performance or VO2peak 
under hypoxic conditions. 
 
To our knowledge, the influence of 
quercetin supplementation on VO2peak 
during simulated altitude using normobaric 
hypoxia has not been investigated. Subudhi 
et al. (25) studied the effects of a 
combination of antioxidants on ventilatory 
threshold at altitude and reported that 30 
days of supplementation improved acute 
ventilatory kinetics associated with 
adaptive responses to hypobaric hypoxia 
(4300meters), but there appeared to be no 
long term benefits associated with the 
supplement. These researchers reported a 
28% reduction in VO2peak at 4300 meters in 
both the control and treatment groups. 
Similarly, we found that VO2peak decreased 
by approximately 17% in both the placebo 
and quercetin supplementation group 
under normobaric hypoxic condition 
studied here (approximately 3600m 
simulated altitude), however there were no 
significant differences in VO2peak associated 
with quercetin supplementation. 
 
Given that some studies have documented 
increased mitochondrial RNA, increased 
muscle blood flow and decreased blood 
pressure in response to quercetin 
supplementation, we felt that quercetin 
supplementation could be particularly 
beneficial to endurance athletes exercising 
at altitude. Our findings indicate no 
beneficial effects of short-term quercetin 
supplementation on VO2peak during 
maximal cycle ergometry testing at a 
simulated altitude of approximately 3600 
meters. The dose used in this investigation 
was determined based on evidence from 
previous research reporting enhanced 
endurance performance after 1-4 weeks of 
quercetin supplementation at similar doses 
to those used here (20, 21). Human studies 
have shown that daily supplementation of 
quercetin (500 mg twice daily) improves 
aerobic capacity (VO2max), time to 
exhaustion, time trial performance, and 
exercise tolerance (20, 21).  Furthermore, 
recent evidence from both animal and 
human studies suggests that quercetin 
supplementation resulted in increased 
mitochondrial capacity, oxidative enzyme 
activity, and increased time to exhaustion 
(8, 9).  Additional data show that quercetin 
may cause vasodilation, resulting in 
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improved blood flow (18, 21, 22).  An 
increase in blood flow to working muscle, 
coupled with an increase in mitochondrial 
density, could result in improved 
endurance performance by increasing an 
individual’s aerobic capacity and fat 
utilization.  Although these data support 
the use of quercetin to improve aerobic 
performance, our findings support those of 
others who have shown that quercetin has 
no effect on aerobic capacity as indicated by 
VO2peak (1,6). 
 
In conclusion, potential beneficial effects of 
quercetin supplementation that may be 
particularly relevant to endurance 
performance at altitude may involve 
structural changes at the muscle cell and 
vascular level (i.e., increased mitochondrial 
density, improved vasodilatory responses), 
therefore, longer durations of 
supplementation should be studied. 
Further, bioavailability of various forms of 
quercetin should be considered and natural 
forms of quercetin supplementation should 
be evaluated. Another area for study is the 
effects of quercetin supplementation and 
dose-response kinetics on untrained 
individual performing at altitude as these 
individuals may benefit more significantly 
from potential upregulation of structural 
components supporting VO2peak and 
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